Methocarbamol (Robaxin) is Safer Than Cyclobenzaprine (Flexeril) During Breastfeeding
Based on available evidence, methocarbamol (Robaxin) appears to be the safer choice during breastfeeding, though neither medication has robust safety data in lactation. The FDA label for methocarbamol explicitly states that the drug and/or its metabolites are excreted in dog milk but notes uncertainty about human milk excretion 1. Cyclobenzaprine has documented transfer into human milk with a relative infant dose of 0.5%, which is generally considered low 2.
Key Safety Considerations
Methocarbamol (Robaxin)
- Limited human lactation data: The FDA label acknowledges that methocarbamol excretion in human milk is unknown, recommending caution when administered to nursing women 1
- No documented adverse infant effects in the available literature
- Lower sedative profile compared to cyclobenzaprine, potentially reducing infant sedation risk
Cyclobenzaprine (Flexeril)
- Documented milk transfer: A 2019 study measured cyclobenzaprine in human milk with a relative infant dose of 0.5%, which is below the theoretical 10% safety threshold 2
- Significant sedative properties: The study recommends regular clinical assessment of infants for drowsiness and poor feeding due to the drug's sedative effects 2
- Pregnancy concerns: A 2014 case report linked maternal cyclobenzaprine use to ductal closure and persistent pulmonary hypertension in a neonate, though this was during pregnancy, not lactation 3
Clinical Recommendation Algorithm
If muscle relaxant therapy is necessary during breastfeeding:
First-line approach: Use NSAIDs (ibuprofen, naproxen, diclofenac) which have extensive safety data in breastfeeding 4
If muscle relaxant required: Choose methocarbamol over cyclobenzaprine
- Use the lowest effective dose for the shortest duration
- Monitor infant for sedation, poor feeding, or unusual drowsiness
Timing strategy: Take medication immediately after breastfeeding to minimize infant exposure at the next feeding
Infant monitoring: Watch for:
- Excessive sedation or lethargy
- Poor feeding or decreased appetite
- Any change in normal behavior patterns
Important Caveats
Neither medication has strong safety evidence in breastfeeding. The 2020 Association of Anaesthetists guideline on breastfeeding medications does not specifically address muscle relaxants like methocarbamol or cyclobenzaprine 4. This absence from comprehensive breastfeeding guidelines reflects the limited data available.
Efficacy concerns: A 2022 emergency department study found that skeletal muscle relaxants (including both methocarbamol and cyclobenzaprine) provided no additional benefit over placebo when combined with NSAIDs for acute low back pain 5. This raises the question of whether these medications are necessary at all, particularly given the uncertainty about breastfeeding safety.
Alternative approach: Given the questionable efficacy of muscle relaxants and limited safety data, strongly consider using NSAIDs alone (ibuprofen or naproxen), which have extensive safety documentation in breastfeeding and may provide equivalent pain relief 4.